Fresenius Kabi Reports the Commercial Availability of Plerixafor Injection

Share this

Fresenius Kabi Reports the Commercial Availability of Plerixafor Injection


  • The company launches Plerixafor inj., a generic equivalent to Mozobil in the US which is available in a 24mg per 1.2 mL single-dose vial
  • Plerixafor, a hematopoietic stem cell mobilizer indicated for the treatment of patients with non-Hodgkin's lymphoma or multiple myeloma in combination with granulocyte-colony stimulating factor. The company broadens healthcare’s most comprehensive portfolio of generic injectable medicines for oncology
  • Additionally, the company also provides 30+ different oncology drugs in the US & reported its first biosimilar in 2022 with the launch of Stimufend, a biosimilar of Neulasta

Ref: Fresenius | Image: Fresenius

Related News:- Fresenius Kabi Launches Idacio (biosimilar, adalimumab) in the US for the Treatment of Chronic Autoimmune Diseases

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions